Literature DB >> 30287599

Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.

Dianne E Sylvester1, Yuyan Chen1, Robyn V Jamieson2, Luciano Dalla-Pozza3, Jennifer A Byrne1.   

Abstract

Genetic predisposition is an important underlying cause of childhood cancer, although the proportion of patients with childhood cancer carrying predisposing pathogenic germline variants is uncertain. This review considers the pathogenic or likely pathogenic germline variants reported by six studies that used next-generation sequencing to investigate genetic predisposition in selected cohorts of patients with childhood cancer and used incompletely overlapping gene sets for analysis and interpretation. These six studies reported that 8.5%-35.5% of patients with childhood cancer carried clinically relevant germline variants. Analysis of 52 autosomal dominant cancer predisposition genes assumed common to all six studies showed that 5.5%-25.8% of patients with childhood cancer carried pathogenic or likely pathogenic germline variants in at least one of these genes. When only non-central nervous system solid tumours (excluding adrenocortical carcinomas) were considered, 8.5%-10.3% of the patients carried pathogenic or likely pathogenic germline variants in at least one of 52 autosomal dominant cancer predisposition genes. There was a lack of concordance between the genotype and phenotype in 33.3%-57.1% of the patients reported with pathogenic or likely pathogenic germline variants, most of which represented variants in autosomal dominant cancer predisposition genes associated with adult onset cancers. In summary, germline genetic testing in patients with childhood cancer requires clear definition of phenotypes and genes considered for interpretation, with potential to inform and broaden childhood cancer predisposition syndromes. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical genetics; paediatric oncology

Mesh:

Substances:

Year:  2018        PMID: 30287599     DOI: 10.1136/jmedgenet-2018-105488

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

Review 1.  Cancer Genetic Counseling-Current Practice and Future Challenges.

Authors:  Jaclyn Schienda; Jill Stopfer
Journal:  Cold Spring Harb Perspect Med       Date:  2020-06-01       Impact factor: 5.159

2.  Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy.

Authors:  Ajay Chatrath; Aakrosh Ratan; Anindya Dutta
Journal:  iScience       Date:  2021-03-04

3.  Hypermethylation of RAD9A intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformation.

Authors:  Danuta Galetzka; Julia Böck; Lukas Wagner; Marcus Dittrich; Olesja Sinizyn; Marco Ludwig; Heidi Rossmann; Claudia Spix; Markus Radsak; Peter Scholz-Kreisel; Johanna Mirsch; Matthias Linke; Walburgis Brenner; Manuela Marron; Alicia Poplawski; Thomas Haaf; Heinz Schmidberger; Dirk Prawitt
Journal:  EXCLI J       Date:  2022-01-07       Impact factor: 4.068

4.  Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features.

Authors:  Thi Minh Kha Nguyen; Astrid Behnert; Torsten Pietsch; Christian Vokuhl; Christian Peter Kratz
Journal:  Fam Cancer       Date:  2021-02-26       Impact factor: 2.375

5.  Effective identification of cancer predisposition syndromes in children with cancer employing a questionnaire.

Authors:  Miriam Schwermer; Astrid Behnert; Beate Dörgeloh; Tim Ripperger; Christian P Kratz
Journal:  Fam Cancer       Date:  2021-03-02       Impact factor: 2.375

6.  Choose and stay on one out of two paths: distinction between clinical versus research genetic testing to identify cancer predisposition syndromes among patients with cancer.

Authors:  Tim Ripperger; D Gareth Evans; David Malkin; Christian P Kratz
Journal:  Fam Cancer       Date:  2021-02-12       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.